Details of the Drug Combinations

General Information of This Drug (ID: DMPH1AG)

Drug Name

TG100801 DMPH1AG

Synonyms

867331-82-6; TG 100801; TG100801; UNII-1VZO7A0J9S; TG-100801; 1VZO7A0J9S; 4-Chloro-3-(5-methyl-3-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)benzo[e][1,2,4]triazin-7-yl)phenyl benzoate; 4-Chloro-3-(5-methyl-3-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-amino)benzo[e][1,2,4]triazin-7-yl)phenyl benzoate; C33H30ClN5O3; CHEMBL403989; SCHEMBL12198196; KS-00001CQP; BDBM97971; DTXSID20235791; MolPort-027-835-464; BCP02570; 3641AC; ABP000364; ZINC29136020; AKOS016008711; CS-0785; DB05075; NCGC00378840-01; KB-81090; HY-10186; TG100-801; W-5618

Indication

Disease Entry	ICD 11	Status	REF
Macular degeneration	9B78.3	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

14 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ABT-263 + TG100801	DCYLI3F	ABT-263	Ewing sarcoma (Cell Line: TC-71)	[2]
Everolimus + TG100801	DCDAYUI	Everolimus	Ewing sarcoma (Cell Line: TC-71)	[3]
Ispinesib + TG100801	DCRZM3Q	Ispinesib	Ewing sarcoma (Cell Line: TC-71)	[3]
Mitomycin + TG100801	DC35CE8	Mitomycin	Ewing sarcoma (Cell Line: TC-71)	[3]
TG100801 + Panobinostat	DCZ9P3Q	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
TG100801 + Panobinostat	DCK8OH1	Panobinostat	Ewing sarcoma (Cell Line: TC-71)	[3]
TG100801 + GDC-0084	DCCTL5N	GDC-0084	Ewing sarcoma (Cell Line: TC-71)	[3]
TG100801 + Exherin	DCXDTGH	Exherin	Ewing sarcoma (Cell Line: TC-71)	[3]
TG100801 + SCH 727965	DC7IBCZ	SCH 727965	Ewing sarcoma (Cell Line: TC-71)	[3]
TG100801 + Ispinesib	DCYNLZO	Ispinesib	Ewing sarcoma (Cell Line: TC-71)	[3]
TG100801 + Mitotane	DCF5P0Q	Mitotane	Ewing sarcoma (Cell Line: TC-71)	[3]
TG100801 + Ruxolitinib	DCU7G4J	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[2]
Tivantinib + TG100801	DCYTXVB	Tivantinib	Ewing sarcoma (Cell Line: TC-71)	[2]
Verteporfin + TG100801	DCK70EY	Verteporfin	Ewing sarcoma (Cell Line: TC-71)	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 14 DrugCom(s)

References

1	ClinicalTrials.gov (NCT00509548) Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD. U.S. National Institutes of Health.
2	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.